Press release

Twist Bioscience Announces Pricing of $78.8 Million Public Offering of Common Stock

Sponsored by Businesswire

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced the pricing of its
underwritten public offering of 3,750,000 shares of its common stock at
a price to the public of $21.00 per share, before underwriting discounts
and commissions. In addition, the company has granted the underwriters
of the offering an option for a period of 30 days to purchase up to an
additional 562,500 shares of the company’s common stock at the public
offering price, less the underwriting discount and commissions. The
gross proceeds of the offering to Twist, before deducting underwriting
discounts and commissions and other offering expenses payable by Twist,
are expected to be $78.8 million, excluding any exercise of the
underwriters’ option to purchase additional shares.

Twist intends to use the net proceeds of the offering, along with its
existing cash, cash equivalents and short-term investments to improve
and update its platform and core technologies by investing in equipment,
expanding its NGS research and development capabilities, investing in
production software, consolidating into new operation facilities and
increasing its production capacity. It also intends to use the proceeds
of the offering to expand its commercial operations including marketing,
NGS sales and technical services in the United States, Europe and Asia,
to continue to expand in the pharmaceutical biologics drug discovery and
DNA data storage markets, to establish its NGS operations in China and
for working capital and general corporate purposes.

The offering is expected to close on or about May 13, 2019, subject to
the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group
L.L.C. are acting as joint book-running managers for the proposed
offering. Robert W. Baird & Co. Incorporated is acting as lead manager.

A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and became effective on May
8, 2019. This offering is being made solely by means of a prospectus.
Copies of the prospectus related to the offering may be obtained from
J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or from Cowen and Company,
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at
(631) 274-2806, or from Evercore Group L.L.C. c/o Equity Capital
Markets, 55 East 52nd Street, 36h Floor, New York, NY 10055,
or by telephone at (888) 474-0200, or by email at

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, the expected closing of the public offering. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the risks and
uncertainties of the ability to attract new customers and retain and
grow sales from existing customers; risks and uncertainties of rapidly
changing technologies and extensive competition in synthetic biology
could make the products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of a significant
customer; risks of third party claims alleging infringement of patents
and proprietary rights or seeking to invalidate Twist Bioscience’s
patents or proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies. For
a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s business in
general, see Twist Bioscience’s risk factors set forth in Twist
Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 2, 2019. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Twist Bioscience specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.